Zentalis Pharmaceuticals regaining worldwide development and commercialization rights to azenosertib, ZN-d5, and ZN-c5 in Greater China is a positive development for the company. This allows them to expand their market and potentially increase revenues, which is likely to have a positive impact on their stock price in the short term.